Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2025-04-03
- Target Recruit Count
- 54
- Registration Number
- NCT06719973
- Locations
- ๐ฏ๐ต
National Cancer Center Hospital - Dept of Respiratory Medicine, Chuo-ku, Japan
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
- Conditions
- Solid TumorsPancreatic CancerGastric CancerPancreatic Ductal Adenocarcinoma (PDAC)Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 250
- Registration Number
- NCT06710132
- Locations
- ๐ฏ๐ต
Saiseikai Kumamoto Hospital - 300175708, Kumamoto-shi, Japan
๐ฐ๐ทKyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
๐ฐ๐ทSamsung Medical Center, Seoul, Korea, Republic of
Anti-GD2 ADC M3554 in Advanced Solid Tumors
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 52
- Registration Number
- NCT06641908
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธMemorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc, New York, New York, United States
๐บ๐ธThe University of Texas MD Anderson Cancer Center, Houston, Texas, United States
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2025-02-26
- Target Recruit Count
- 54
- Registration Number
- NCT06509906
- Locations
- ๐บ๐ธ
Sarah Cannon Research Institute at Health One, Denver, Colorado, United States
๐บ๐ธCarolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Pennington, New Jersey, United States
๐บ๐ธVanderbilt University - 150912667, Nashville, Tennessee, United States
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2025-02-03
- Target Recruit Count
- 60
- Registration Number
- NCT06433219
- Locations
- ๐ต๐ฑ
MICS Centrum Medyczne Torun - Medicovernn, Torun, Poland
๐ช๐ธHospital Clinic de Barcelona - Servicio de Oncologia, Barcelona, Spain
๐ช๐ธICO Girona - Hospital Universitari de Girona Dr Josep Trueta - Servicio de Oncologia Medica, Girona, Spain
Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 70
- Registration Number
- NCT06424717
- Locations
- ๐ฉ๐ช
Please Contact the Communication Center, Darmstadt, Germany
๐บ๐ธPlease Contact U.S. Medical Information, Rockland, Massachusetts, United States
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2025-05-13
- Target Recruit Count
- 96
- Registration Number
- NCT06421935
- Locations
- ๐ฐ๐ท
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
๐ฐ๐ทSamsung Medical Center, Seoul, Korea, Republic of
๐ฐ๐ทSeoul National University Hospital, Seoul, Korea, Republic of
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-07-18
- Target Recruit Count
- 18
- Registration Number
- NCT06056310
- Locations
- ๐บ๐ธ
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
๐บ๐ธMontefiore Medical Center PRIME, Bronx, New York, United States
๐ง๐ชUniversitair Ziekenhuis Gent - Medical Oncology, Gent, Belgium
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2025-01-27
- Target Recruit Count
- 180
- Registration Number
- NCT05882734
- Locations
- ๐ง๐ช
CHU de Liรจge - PARENT, Liege, Belgium
๐บ๐ธUPMC Cancer Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธUCLA Hematology and Oncology - Santa Monica, Santa Monica, California, United States
Study of M5049 in DM and PM Participants (NEPTUNIA)
- Conditions
- PolymyositisDermatomyositis
- Interventions
- Drug: PlaceboDrug: M5049 high dose
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-05-14
- Target Recruit Count
- 40
- Registration Number
- NCT05650567
- Locations
- ๐ฎ๐น
Arcispedale S. Maria Nuova, Reggio Emilia, Italy
๐ช๐ธHospital Vall d'Hebron, Barcelona, Spain
๐ฎ๐นFondazione Policlinico Universitario A. Gemelli-IRCCS, UCSC - Scienze Mediche e Chirurgiche, Rome, Italy